Kinase drug discovery 20 years after imatinib: progress and future directions.
Journal
Nature reviews. Drug discovery
ISSN: 1474-1784
Titre abrégé: Nat Rev Drug Discov
Pays: England
ID NLM: 101124171
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
26
03
2021
pubmed:
19
5
2021
medline:
17
8
2021
entrez:
18
5
2021
Statut:
ppublish
Résumé
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or mutations in their genes, cause cancer and other diseases. Here, we review the remarkable progress made over the past 20 years in improving the potency and specificity of small-molecule inhibitors of protein and lipid kinases, resulting in the approval of more than 70 new drugs since imatinib was approved in 2001. These compounds have had a significant impact on the way in which we now treat cancers and non-cancerous conditions. We discuss how the challenge of drug resistance to kinase inhibitors is being met and the future of kinase drug discovery.
Identifiants
pubmed: 34002056
doi: 10.1038/s41573-021-00195-4
pii: 10.1038/s41573-021-00195-4
pmc: PMC8127496
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-569Subventions
Organisme : Medical Research Council
ID : MR/R021406/1
Pays : United Kingdom
Références
Cohen, P. Protein kinases — the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309–315 (2002). A review of the history of the development of protein kinase inhibitors up to the time that imatinib was approved for clinical use, and which provides the background to this article.
pubmed: 12120282
doi: 10.1038/nrd773
Witte, O. N., Dasgupta, A. & Baltimore, D. Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature 283, 826–831 (1980).
pubmed: 6244493
doi: 10.1038/283826a0
Veale, D., Ashcroft, T., Marsh, C., Gibson, G. J. & Harris, A. L. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer 55, 513–516 (1987).
pubmed: 3038157
pmcid: 2001730
doi: 10.1038/bjc.1987.104
Haeder, M. et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res. 48, 1132–1136 (1988).
pubmed: 2830015
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
pubmed: 15118073
doi: 10.1056/NEJMoa040938
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
pubmed: 15118125
doi: 10.1126/science.1099314
Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).
pubmed: 15329413
pmcid: 516528
doi: 10.1073/pnas.0405220101
Shigematsu, H. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97, 339–346 (2005).
pubmed: 15741570
doi: 10.1093/jnci/dji055
Berger, A. H. et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell 30, 214–228 (2016).
pubmed: 27478040
pmcid: 5003022
doi: 10.1016/j.ccell.2016.06.022
Campbell, J. D. et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48, 607–616 (2016).
pubmed: 27158780
pmcid: 4884143
doi: 10.1038/ng.3564
Breccia, M. & Alimena, G. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk. Res. 34, 129–134 (2010).
pubmed: 19783301
doi: 10.1016/j.leukres.2009.08.031
Kantarjian, H., Jabbour, E., Grimley, J. & Kirkpatrick, P. Dasatinib. Nat. Rev. Drug Discov. 5, 717–718 (2006).
pubmed: 17001803
doi: 10.1038/nrd2135
Mealing, S. et al. The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp. Hematol. Oncol. 2, 5 (2013).
pubmed: 23422286
pmcid: 3585848
doi: 10.1186/2162-3619-2-5
Cortes, J. E. et al. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Curr. Med. Res. Opin. 35, 1615–1622 (2019).
pubmed: 30964361
doi: 10.1080/03007995.2019.1605239
Redaelli, S. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol. 27, 469–471 (2009).
pubmed: 19075254
doi: 10.1200/JCO.2008.19.8853
Cortes, J. E. et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J. Clin. Oncol. 36, 231–237 (2018).
pubmed: 29091516
doi: 10.1200/JCO.2017.74.7162
Noronha, G. et al. Inhibitors of ABL and the ABL-T315I mutation. Curr. Top. Med. Chem. 8, 905–921 (2008).
pubmed: 18673174
doi: 10.2174/156802608784911635
O’Hare, T., Zabriskie, M. S., Eiring, A. M. & Deininger, M. W. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat. Rev. Cancer 12, 513–526 (2012).
pubmed: 22825216
doi: 10.1038/nrc3317
O’Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401–412 (2009).
pubmed: 19878872
pmcid: 2804470
doi: 10.1016/j.ccr.2009.09.028
Moy, B., Kirkpatrick, P., Kar, S. & Goss, P. Lapatinib. Nat. Rev. Drug Discov. 6, 431–432 (2007).
pubmed: 17633789
doi: 10.1038/nrd2332
Christensen, J. G. et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314–3322 (2007). An interesting preclinical example of the polypharmacology of a kinase inhibitor.
pubmed: 18089725
doi: 10.1158/1535-7163.MCT-07-0365
Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).
pubmed: 20979469
pmcid: 3014291
doi: 10.1056/NEJMoa1006448
Solomon, B. J. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167–2177 (2014).
pubmed: 25470694
doi: 10.1056/NEJMoa1408440
Mok, T. et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann. Oncol. 31, 1056–1064 (2020).
pubmed: 32418886
doi: 10.1016/j.annonc.2020.04.478
Peters, S. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
pubmed: 28586279
doi: 10.1056/NEJMoa1704795
Camidge, D. R. et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 379, 2027–2039 (2018).
pubmed: 30280657
doi: 10.1056/NEJMoa1810171
Shaw, A. T. et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N. Engl. J. Med. 383, 2018–2029 (2020).
pubmed: 33207094
doi: 10.1056/NEJMoa2027187
Rajabi, M. & Mousa, S. A. The role of angiogenesis in cancer treatment. Biomedicines 5, 34 (2017).
pmcid: 5489820
doi: 10.3390/biomedicines5020034
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
pubmed: 18650514
doi: 10.1056/NEJMoa0708857
Faivre, S., Demetri, G., Sargent, W. & Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6, 734–745 (2007).
pubmed: 17690708
doi: 10.1038/nrd2380
Bukowski, R. M., Yasothan, U. & Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Discov. 9, 17–18 (2010).
pubmed: 20043026
doi: 10.1038/nrd3073
Keating, G. M. Axitinib: a review in advanced renal cell carcinoma. Drugs 75, 1903–1913 (2015).
pubmed: 26487541
doi: 10.1007/s40265-015-0483-x
Rathi, N., Maughan, B. L., Agarwal, N. & Swami, U. Mini-review: cabozantinib in the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. Cancer Manag. Res. 12, 3741–3749 (2020).
pubmed: 32547210
pmcid: 7246323
doi: 10.2147/CMAR.S202973
Davies, S. P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000).
pubmed: 10998351
pmcid: 1221339
doi: 10.1042/bj3510095
Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315 (2007). This paper and Davies et al. (2000) introduce and popularize the use of kinase profiling panels to assess the specificities of kinase inhibitors.
pubmed: 17850214
pmcid: 2267365
doi: 10.1042/BJ20070797
Yang, G. et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood 127, 3237–3252 (2016).
pubmed: 27143257
doi: 10.1182/blood-2016-01-695098
Shaw, A. T. et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371, 1963–1971 (2014).
pubmed: 25264305
pmcid: 4264527
doi: 10.1056/NEJMoa1406766
Rodig, S. J. & Shapiro, G. I. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr. Opin. Investig. Drugs 11, 1477–1490 (2010).
pubmed: 21154129
Suh, K. J. et al. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. Int. J. Hematol. 106, 229–239 (2017).
pubmed: 28378056
doi: 10.1007/s12185-017-2225-1
Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, eaan4368 (2017).
Elkins, J. M. et al. Comprehensive characterization of the published kinase inhibitor set. Nat. Biotechnol. 34, 95–103 (2016).
pubmed: 26501955
doi: 10.1038/nbt.3374
Ciceri, P. et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 10, 305–312 (2014). The paper demonstrating that protein kinases inhibitors frequently bind to BRD-containing proteins, and that dual kinase–BRD inhibitors can be designed rationally.
pubmed: 24584101
pmcid: 3998711
doi: 10.1038/nchembio.1471
Malik, N. et al. Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. Biochem. J. 468, 363–372 (2015).
pubmed: 25891802
doi: 10.1042/BJ20141523
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).
Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).
Kolch, W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351, 289–305 (2000).
pubmed: 11023813
pmcid: 1221363
doi: 10.1042/bj3510289
Roy, F., Laberge, G., Douziech, M., Ferland-McCollough, D. & Therrien, M. KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev. 16, 427–438 (2002).
pubmed: 11850406
pmcid: 155344
doi: 10.1101/gad.962902
Terrell, E. M. & Morrison, D. K. Ras-mediated activation of the Raf family kinases. Cold Spring Harb. Perspect. Med. 9, a033746 (2019).
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002). This study exploits the sequence of the human genome to identify protein kinases mutated in human cancers. The analysis reveals the prevalence of the BRAF
pubmed: 12068308
doi: 10.1038/nature00766
Peng, S. B. et al. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell 28, 384–398 (2015).
pubmed: 26343583
doi: 10.1016/j.ccell.2015.08.002
Robert, C. et al. Five-year outcomes with dabrafenib plus trametinib in metastaticmelanoma. N. Engl. J. Med. 381, 626–636 (2019). Review of the clinical studies that revealed the remarkable improvement in the treatment of metastatic melanoma produced by combining inhibitors of BRAF and MEK, compared with either kinase inhibitor used alone.
pubmed: 31166680
doi: 10.1056/NEJMoa1904059
Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).
pubmed: 28891408
doi: 10.1056/NEJMoa1708539
Dummer, R. et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N. Engl. J. Med. 383, 1139–1148 (2020).
pubmed: 32877599
doi: 10.1056/NEJMoa2005493
Planchard, D. et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 17, 984–993 (2016).
pubmed: 27283860
pmcid: 4993103
doi: 10.1016/S1470-2045(16)30146-2
Planchard, D. et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 18, 1307–1316 (2017).
pubmed: 28919011
doi: 10.1016/S1470-2045(17)30679-4
Hall-Jackson, C. A. et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559–568 (1999).
pubmed: 10421767
doi: 10.1016/S1074-5521(99)80088-X
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010).
pubmed: 20179705
pmcid: 3178447
doi: 10.1038/nature08902
Karoulia, Z., Gavathiotis, E. & Poulikakos, P. I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 17, 676–691 (2017).
pubmed: 28984291
pmcid: 6000833
doi: 10.1038/nrc.2017.79
Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207–215 (2012).
pubmed: 22256804
pmcid: 3724537
doi: 10.1056/NEJMoa1105358
Khan, Z. M. et al. Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature 588, 509–514 (2020).
pubmed: 32927473
pmcid: 7746607
doi: 10.1038/s41586-020-2760-4
Poh, A. Dual RAF-MEK inhibitor assessed. Cancer Discov. 11, 5–6 (2020).
van Geel, R. et al. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer. Br. J. Cancer 122, 1166–1174 (2020).
pubmed: 32147669
pmcid: 7156736
doi: 10.1038/s41416-020-0776-z
de Miguel, M. & Calvo, E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell 38, 326–333 (2020).
pubmed: 32750319
doi: 10.1016/j.ccell.2020.07.004
Giraldo, N. A. et al. The clinical role of the TME in solid cancer. Br. J. Cancer 120, 45–53 (2019).
pubmed: 30413828
doi: 10.1038/s41416-018-0327-z
Baldewijns, M. M. et al. VHL and HIF signalling in renal cell carcinogenesis. J. Pathol. 221, 125–138 (2010).
pubmed: 20225241
doi: 10.1002/path.2689
Liu, P. et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat. Commun. 10, 1486 (2019). The first evidence that a protein TKI is capable of inducing immunogenic cell death.
pubmed: 30940805
pmcid: 6445096
doi: 10.1038/s41467-019-09415-3
Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013).
pubmed: 23307859
pmcid: 3752683
doi: 10.1158/1078-0432.CCR-12-1630
Dummer, R. et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat. Med. 26, 1557–1563 (2020).
pubmed: 33020648
doi: 10.1038/s41591-020-1082-2
P. Nathan, R. D. et al. LBA43 - Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. Ann. Oncol. 31, S1142–S1215 (2020).
doi: 10.1016/j.annonc.2020.08.2273
Yang, J. C. et al. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL Brief Report. J. Thorac. Oncol. 14, 933–939 (2019).
pubmed: 30763730
doi: 10.1016/j.jtho.2019.02.001
Spigel, D. R. et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370). J. Thorac. Oncol. 13, 682–688 (2018).
pubmed: 29518553
doi: 10.1016/j.jtho.2018.02.022
Glodde, N. et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity 47, 789–802.e789 (2017).
pubmed: 29045907
doi: 10.1016/j.immuni.2017.09.012
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04139317 (2021).
Hemmings, B. A. & Restuccia, D. F. PI3K-PKB/Akt pathway. Cold Spring Harb. Perspect. Biol. 4, a011189 (2012).
pubmed: 22952397
pmcid: 3428770
doi: 10.1101/cshperspect.a011189
Flinn, I. W. et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123, 3406–3413 (2014).
pubmed: 24615776
pmcid: 4260978
doi: 10.1182/blood-2013-11-538546
Sapon-Cousineau, V., Sapon-Cousineau, S. & Assouline, S. PI3K inhibitors and their role as novel agents for targeted therapy in lymphoma. Curr. Treat. Options Oncol. 21, 51 (2020).
pubmed: 32356174
doi: 10.1007/s11864-020-00746-8
Andre, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940 (2019).
pubmed: 31091374
doi: 10.1056/NEJMoa1813904
Smyth, L. M. et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 E17K-mutant, ER-positive metastatic breast cancer. Clin. Cancer Res. 26, 3947–3957 (2020).
pubmed: 32312891
pmcid: 7415507
doi: 10.1158/1078-0432.CCR-19-3953
Rudolph, M. et al. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer 16, 622 (2016).
pubmed: 27515171
pmcid: 4982009
doi: 10.1186/s12885-016-2626-1
Jones, R. H. et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 21, 345–357 (2020).
pubmed: 32035020
pmcid: 7052734
doi: 10.1016/S1470-2045(19)30817-4
Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).
pubmed: 20573926
doi: 10.1056/NEJMoa0909530
Oizumi, S. et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 17, 863–870 (2012).
pubmed: 22581822
pmcid: 3380886
doi: 10.1634/theoncologist.2011-0426
Hosomi, Y. et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J. Clin. Oncol. 38, 115–123 (2020).
pubmed: 31682542
doi: 10.1200/JCO.19.01488
Noronha, V. et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J. Clin. Oncol. 38, 124–136 (2020).
pubmed: 31411950
doi: 10.1200/JCO.19.01154
Reungwetwattana, T. et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 3290–3297 (2018).
doi: 10.1200/JCO.2018.78.3118
Camidge, D. R. et al. Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. J. Clin. Oncol. 36, 2693–2701 (2018).
pubmed: 29768119
doi: 10.1200/JCO.2017.77.5841
Solomon, B. J. et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 19, 1654–1667 (2018).
pubmed: 30413378
doi: 10.1016/S1470-2045(18)30649-1
Subbiah, V. et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann. Oncol. 29, 1869–1876 (2018).
pubmed: 29912274
pmcid: 6096733
doi: 10.1093/annonc/mdy137
Lin, J. J. et al. Efficacy of alectinib in patients with ALK-positive NSCLC and symptomatic or large CNS metastases. J. Thorac. Oncol. 14, 683–690 (2019).
pubmed: 30529198
doi: 10.1016/j.jtho.2018.12.002
Yang, J. C. H. et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J. Clin. Oncol. 38, 538–547 (2020).
pubmed: 31809241
doi: 10.1200/JCO.19.00457
Ou, S. H., Sommers, K. R., Azada, M. C. & Garon, E. B. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 20, 224–226 (2015).
pubmed: 25568147
pmcid: 4319629
doi: 10.1634/theoncologist.2014-0309
Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17, 333–351 (2016).
pubmed: 27184599
doi: 10.1038/nrg.2016.49
Cescon, D. W., Bratman, S. V., Chan, S. M. & Siu, L. L. Circulating tumor DNA and liquid biopsy in oncology. Nat. Cancer 1, 276–290 (2020). This review discusses the current landscape of ctDNA liquid-biopsy applications across cancer and highlights opportunities for clinical investigation.
pubmed: 35122035
doi: 10.1038/s43018-020-0043-5
Li, J. W., Cao, S. H., Xu, J. L. & Zhong, H. De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors. Cancer Biol. Ther. 20, 1183–1186 (2019).
pubmed: 31131689
pmcid: 6741769
doi: 10.1080/15384047.2019.1617568
Yu, H. A. et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann. Oncol. 25, 423–428 (2014).
pubmed: 24478319
pmcid: 3905781
doi: 10.1093/annonc/mdt573
Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 10, 1174–1193 (2020).
pubmed: 32404308
pmcid: 8815415
doi: 10.1158/2159-8290.CD-19-1390
Guo, R. et al. MET inhibitor resistance in patients with MET exon 14-altered lung cancers. J. Clin. Oncol. 37, 9006–9006 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.9006
Lovly, C. M. & Shaw, A. T. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res. 20, 2249–2256 (2014).
pubmed: 24789032
pmcid: 4029617
doi: 10.1158/1078-0432.CCR-13-1610
Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18, 452–464 (2018).
pubmed: 29643473
pmcid: 6622180
doi: 10.1038/s41568-018-0005-8
Eyers, P. A., Craxton, M., Morrice, N., Cohen, P. & Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 5, 321–328 (1998).
pubmed: 9653550
doi: 10.1016/S1074-5521(98)90170-3
Clark, K. et al. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc. Natl Acad. Sci. USA 109, 16986–16991 (2012).
pubmed: 23033494
pmcid: 3479463
doi: 10.1073/pnas.1215450109
Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001). One of the first examples of clinical drug resistance to a kinase inhibitor mediated by a gatekeeper mutation.
pubmed: 11423618
doi: 10.1126/science.1062538
Nguyen, K. S., Kobayashi, S. & Costa, D. B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer 10, 281–289 (2009).
pubmed: 19632948
pmcid: 2758558
doi: 10.3816/CLC.2009.n.039
Yun, C. H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105, 2070–2075 (2008).
pubmed: 18227510
pmcid: 2538882
doi: 10.1073/pnas.0709662105
Drilon, A. et al. Repotrectinib (TPX-0005) Is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations. Cancer Discov. 8, 1227–1236 (2018).
pubmed: 30093503
doi: 10.1158/2159-8290.CD-18-0484
Solomon, B. J. et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J. Thorac. Oncol. 15, 541–549 (2020).
pubmed: 31988000
pmcid: 7430178
doi: 10.1016/j.jtho.2020.01.006
Cocco, E. et al. TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. Cancer Discov. 11, 126–141 (2021).
pubmed: 33004339
doi: 10.1158/2159-8290.CD-20-0571
Volm, M. & Efferth, T. Prediction of cancer drug resistance and implications for personalized medicine. Front. Oncol. 5, 282 (2015).
pubmed: 26734568
pmcid: 4681783
doi: 10.3389/fonc.2015.00282
Husain, H. et al. Strategies to overcome bypass mechanisms mediating clinical resistance to EGFR tyrosine kinase inhibition in lung cancer. Mol. Cancer Ther. 16, 265–272 (2017).
pubmed: 28159915
doi: 10.1158/1535-7163.MCT-16-0105
Lin, J. J. et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann. Oncol. 31, 1725–1733 (2020).
pubmed: 33007380
doi: 10.1016/j.annonc.2020.09.015
Lavaud, P. & Andre, F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med. 12, 132 (2014).
pubmed: 25285786
pmcid: 4243818
doi: 10.1186/s12916-014-0132-3
D’Amato, V. et al. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat. Rev. 41, 877–883 (2015).
pubmed: 26276735
doi: 10.1016/j.ctrv.2015.08.001
Yang, C. et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene 36, 2255–2264 (2017).
pubmed: 27748766
doi: 10.1038/onc.2016.379
Herrera-Abreu, M. T. et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 76, 2301–2313 (2016).
pubmed: 27020857
pmcid: 5426059
doi: 10.1158/0008-5472.CAN-15-0728
Min, A. et al. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. Cancer Lett. 430, 123–132 (2018).
pubmed: 29729292
doi: 10.1016/j.canlet.2018.04.037
Pandey, K. et al. Combined CDK2 and CDK4/6 inhibition overcomes palbociclib resistance in breast cancer by enhancing senescence. Cancers 12, 3566 (2020).
Bordi, P. et al. Detection of ALK and KRAS mutations in circulating tumor DNA of patients with advanced ALK-positive NSCLC with disease progression during crizotinib treatment. Clin. Lung Cancer 18, 692–697 (2017).
pubmed: 28601386
doi: 10.1016/j.cllc.2017.04.013
Suzawa, K. et al. Activation of KRAS mediates resistance to targeted therapy in MET exon 14-mutant non-small cell lung cancer. Clin. Cancer Res. 25, 1248–1260 (2019).
pubmed: 30352902
doi: 10.1158/1078-0432.CCR-18-1640
Ohashi, K. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl Acad. Sci. USA 109, E2127–E2133 (2012).
pubmed: 22773810
pmcid: 3411967
doi: 10.1073/pnas.1203530109
de Bruin, E. C. et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 4, 606–619 (2014).
pubmed: 24535670
pmcid: 4011693
doi: 10.1158/2159-8290.CD-13-0741
Jamme, P. et al. Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations. J. Thorac. Oncol. 15, 741–751 (2020).
pubmed: 32169477
doi: 10.1016/j.jtho.2020.01.027
Costa, C. et al. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. Cancer Discov. 10, 72–85 (2020).
pubmed: 31594766
doi: 10.1158/2159-8290.CD-18-0830
Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518, 240–244 (2015).
pubmed: 25409150
doi: 10.1038/nature13948
Sos, M. L. et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69, 3256–3261 (2009).
pubmed: 19351834
pmcid: 2849653
doi: 10.1158/0008-5472.CAN-08-4055
Solca, F. et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343, 342–350 (2012).
pubmed: 22888144
doi: 10.1124/jpet.112.197756
Engelman, J. A. et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67, 11924–11932 (2007).
pubmed: 18089823
doi: 10.1158/0008-5472.CAN-07-1885
Cross, D. A. E. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR Inhibitors in lung cancer. Cancer Discov. 4, 1046–1061 (2014).
pubmed: 24893891
pmcid: 4315625
doi: 10.1158/2159-8290.CD-14-0337
Kim, E. S. Olmutinib: first global approval. Drugs 76, 1153–1157 (2016).
pubmed: 27357069
doi: 10.1007/s40265-016-0606-z
Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung Ccancer. N. Engl. J. Med. 376, 629–640 (2017).
pubmed: 27959700
doi: 10.1056/NEJMoa1612674
Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).
pubmed: 29151359
doi: 10.1056/NEJMoa1713137
Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41–50 (2019).
pubmed: 31751012
doi: 10.1056/NEJMoa1913662
Leonetti, A. et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer 121, 725–737 (2019).
pubmed: 31564718
pmcid: 6889286
doi: 10.1038/s41416-019-0573-8
Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560–562 (2015).
pubmed: 25939061
pmcid: 4771182
doi: 10.1038/nm.3854
Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl Med. 4, 120ra117 (2012).
doi: 10.1126/scitranslmed.3003316
Crinò, L. et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J. Clin. Oncol. 34, 2866–2873 (2016).
pubmed: 27432917
doi: 10.1200/JCO.2015.65.5936
Shaw, A. T. et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 17, 234–242 (2016).
pubmed: 26708155
doi: 10.1016/S1470-2045(15)00488-X
Gettinger, S. N. et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 17, 1683–1696 (2016).
pubmed: 27836716
doi: 10.1016/S1470-2045(16)30392-8
Gainor, J. F. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6, 1118–1133 (2016).
pubmed: 27432227
pmcid: 5050111
doi: 10.1158/2159-8290.CD-16-0596
Yoda, S. et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 8, 714–729 (2018).
pubmed: 29650534
pmcid: 5984716
doi: 10.1158/2159-8290.CD-17-1256
Recondo, G. et al. Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clin. Cancer Res. 26, 242–255 (2020).
pubmed: 31585938
doi: 10.1158/1078-0432.CCR-19-1104
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002). The comprehensive classification and annotation of the 500 plus protein kinases (the human kinome) and its subdivision into subfamilies, which has greatly facilitated the understanding of kinome relationships.
pubmed: 12471243
doi: 10.1126/science.1075762
Morgan Jones, M. et al. The Structural Genomics Consortium: A Knowledge Platform for Drug Discovery (RAND Corporation, 2014).
Murray, C. W. & Blundell, T. L. Structural biology in fragment-based drug design. Curr. Opin. Struct. Biol. 20, 497–507 (2010).
pubmed: 20471246
doi: 10.1016/j.sbi.2010.04.003
Thomas, S. E. et al. Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping. Phil. Trans. R. Soc. A 377, 20180422 (2019).
pubmed: 31030650
pmcid: 6501894
doi: 10.1098/rsta.2018.0422
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R. & Gunning, P. T. Advances in covalent kinase inhibitors. Chem. Soc. Rev. 49, 2617–2687 (2020).
pubmed: 32227030
doi: 10.1039/C9CS00720B
Liu, Q. et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20, 146–159 (2013). This article and Abdeldayem et al. (2020) review advances in developing kinase inhibitors that bind covalently to conserved cysteine residues located near the catalytic site, and contributed to the increasing numbers of these inhibitors that are being developed and approved for clinical use.
pubmed: 23438744
pmcid: 3583020
doi: 10.1016/j.chembiol.2012.12.006
Arighi, E., Borrello, M. G. & Sariola, H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor. Rev. 16, 441–467 (2005).
pubmed: 15982921
doi: 10.1016/j.cytogfr.2005.05.010
Gautschi, O. et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. J. Clin. Oncol. 35, 1403–1410 (2017).
pubmed: 28447912
pmcid: 5559893
doi: 10.1200/JCO.2016.70.9352
Drilon, A. et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N. Engl. J. Med. 383, 813–824 (2020).
pubmed: 32846060
pmcid: 7506467
doi: 10.1056/NEJMoa2005653
Subbiah, V. et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 8, 836–849 (2018).
pubmed: 29657135
doi: 10.1158/2159-8290.CD-18-0338
Kollareddy, M. et al. Aurora kinase inhibitors: progress towards the clinic. Invest. New Drugs 30, 2411–2432 (2012).
pubmed: 22350019
pmcid: 3484309
doi: 10.1007/s10637-012-9798-6
Komlodi-Pasztor, E., Sackett, D. L. & Fojo, A. T. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin. Cancer Res. 18, 51–63 (2012).
pubmed: 22215906
doi: 10.1158/1078-0432.CCR-11-0999
Sherr, C. J. & Bartek, J. Cell cycle–targeted cancer therapies. Annu. Rev. Cancer Biol. 1, 41–57 (2017).
doi: 10.1146/annurev-cancerbio-040716-075628
Ashton, S. et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci. Transl Med. 8, 325ra317 (2016).
doi: 10.1126/scitranslmed.aad2355
Heffron, T. P. Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels. Neuro-Oncol. 20, 307–312 (2017).
pmcid: 5817959
doi: 10.1093/neuonc/nox179
Skerratt, S. E. & Storer, R. I. in Kinase Drug Discovery: Modern Approaches (eds Ward, R. A. & Goldberg, F. W.) 128–180 (Royal Society of Chemistry, 2019). This article and Heffron (2017) discuss the unmet need for kinase inhibitors to achieve free brain penetration, and the chemistry design approaches and challenges to achieve inhibitors with appropriate properties.
Johnson, T. W. et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J. Med. Chem. 57, 4720–4744 (2014).
pubmed: 24819116
doi: 10.1021/jm500261q
Zeng, Q. et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J. Med. Chem. 58, 8200–8215 (2015).
pubmed: 26313252
doi: 10.1021/acs.jmedchem.5b01073
Shibuya, M. & Suzuki, Y. Treatment of cerebral vasospasm by a protein kinase inhibitor AT 877 [Japanese]. No Shinkei 45, 819–824 (1993).
Doggrell, S. A. Rho-kinase inhibitors show promise in pulmonary hypertension. Expert Opin. Investig. Drugs 14, 1157–1159 (2005).
pubmed: 16144499
doi: 10.1517/13543784.14.9.1157
Nagumo, H. et al. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am. J. Physiol. Cell Physiol. 278, C57–65 (2000).
pubmed: 10644512
doi: 10.1152/ajpcell.2000.278.1.C57
Heitman, J., Movva, N. R. & Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905–909 (1991).
pubmed: 1715094
doi: 10.1126/science.1715094
Cohen, P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 21, 317–324 (2009).
pubmed: 19217767
doi: 10.1016/j.ceb.2009.01.015
Zarrin, A. A., Bao, K., Lupardus, P. & Vucic, D. Kinase inhibition in autoimmunity and inflammation. Nat. Rev. Drug Discov. 20, 39–63 (2021).
pubmed: 33077936
doi: 10.1038/s41573-020-0082-8
Shuai, K. & Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3, 900–911 (2003).
pubmed: 14668806
doi: 10.1038/nri1226
Fragoulis, G. E., McInnes, I. B. & Siebert, S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology 58, i43–i54 (2019). Recent review of the increasing number of JAK inhibitors being developed for the treatment of rheumatoid arthritis and other immune diseases.
pubmed: 30806709
pmcid: 6390879
doi: 10.1093/rheumatology/key276
A, T. V., Haikarainen, T., Raivola, J. & Silvennoinen, O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs 33, 15–32 (2019).
doi: 10.1007/s40259-019-00333-w
Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054–1061 (2005).
pubmed: 15781101
doi: 10.1016/S0140-6736(05)71142-9
Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779–1790 (2005).
pubmed: 15858187
doi: 10.1056/NEJMoa051113
Kuykendall, A. T. et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann. Hematol. 97, 435–441 (2018).
pubmed: 29189896
doi: 10.1007/s00277-017-3194-4
Talpaz, M., Erickson-Viitanen, S., Hou, K., Hamburg, S. & Baer, M. R. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study. J. Hematol. Oncol. 11, 101 (2018).
pubmed: 30086777
pmcid: 6081850
doi: 10.1186/s13045-018-0642-0
Kim, T. W. et al. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J. Exp. Med. 204, 1025–1036 (2007).
pubmed: 17470642
pmcid: 2118590
doi: 10.1084/jem.20061825
Nanda, S. K. et al. Distinct signals and immune cells drive liver pathology and glomerulonephritis in ABIN1[D485N] mice. Life Sci. Alliance 2, e201900533 (2019).
Seganish, W. M. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012–2015). Expert. Opin. Ther. Pat. 26, 917–932 (2016).
pubmed: 27310003
doi: 10.1080/13543776.2016.1202926
Picard, C., Casanova, J. L. & Puel, A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin. Microbiol. Rev. 24, 490–497 (2011).
pubmed: 21734245
pmcid: 3131061
doi: 10.1128/CMR.00001-11
Picard, C. et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine 89, 403–425 (2010). Review of the remarkable long-term clinical study of IRAK4-deficient patients, which revealed why IRAK4 inhibition is unlikely to cause life-threatening microbial infections in adults, and de-risked this drug target.
pubmed: 21057262
doi: 10.1097/MD.0b013e3181fd8ec3
Danto, S. I. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects. Arthritis Res. Ther. 21, 269 (2019).
pubmed: 31805989
pmcid: 6896740
doi: 10.1186/s13075-019-2008-6
Wiese, M. D., Manning-Bennett, A. T. & Abuhelwa, A. Y. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin. Investig. Drugs 29, 475–482 (2020).
pubmed: 32255710
doi: 10.1080/13543784.2020.1752660
Darling, N. J., Toth, R., Arthur, J. S. & Clark, K. Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages. Biochem. J. 474, 521–537 (2017).
pubmed: 27920213
doi: 10.1042/BCJ20160646
Galapagos. Galapagos’ R&D Roundtable showcases Toledo program. GlobeNewswire https://www.globenewswire.com/news-release/2020/10/27/2115341/0/en/Galapagos-R-D-Roundtable-showcases-Toledo-program.html (2020).
Mujahid, N. et al. A UV-independent topical small-molecule approach for melanin production in human skin. Cell Rep. 19, 2177–2184 (2017).
pubmed: 28614705
pmcid: 5549921
doi: 10.1016/j.celrep.2017.05.042
Wein, M. N. et al. SIKs control osteocyte responses to parathyroid hormone. Nat. Commun. 7, 13176 (2016).
pubmed: 27759007
pmcid: 5075806
doi: 10.1038/ncomms13176
Kim, M. K. et al. Salt-inducible kinase 1 regulates bone anabolism via the CRTC1-CREB-Id1 axis. Cell Death Dis. 10, 826 (2019).
pubmed: 31672960
pmcid: 6823377
doi: 10.1038/s41419-019-1915-4
Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746 (1994).
pubmed: 7997261
doi: 10.1038/372739a0
Cuenda, A. et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229–233 (1995).
pubmed: 7750577
doi: 10.1016/0014-5793(95)00357-F
Eyers, P. A., van den, I. P., Quinlan, R. A., Goedert, M. & Cohen, P. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett. 451, 191–196 (1999).
pubmed: 10371163
doi: 10.1016/S0014-5793(99)00552-9
Hammaker, D. & Firestein, G. S. “Go upstream, young man”: lessons learned from the p38 saga. Ann. Rheum. Dis. 69, i77–i82 (2010).
pubmed: 19995751
doi: 10.1136/ard.2009.119479
Alam, J. J. Selective brain-targeted antagonism of p38 MAPKα reduces hippocampal IL-1β levels and improves Morris water maze performance in aged rats. J. Alzheimers Dis. 48, 219–227 (2015).
pubmed: 26401942
pmcid: 4923728
doi: 10.3233/JAD-150277
Alam, J., Blackburn, K. & Patrick, D. Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38α to reverse synaptic dysfunction in early Alzheimer’s disease. J. Prev. Alzheimers Dis. 4, 273–278 (2017).
pubmed: 29181493
Fagiani, F., Lanni, C., Racchi, M. & Govoni, S. Targeting dementias through cancer kinases inhibition. Alzheimers Dement. 6, e12044 (2020).
Cohen, P. & Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 3, 479–487 (2004).
pubmed: 15173837
doi: 10.1038/nrd1415
Martinez, A., Alonso, M., Castro, A., Pérez, C. & Moreno, F. J. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease. J. Med. Chem. 45, 1292–1299 (2002).
pubmed: 11881998
doi: 10.1021/jm011020u
Serenó, L. et al. A novel GSK-3beta inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 35, 359–367 (2009).
pubmed: 19523516
doi: 10.1016/j.nbd.2009.05.025
Paisán-Ruiz, C., Lewis, P. A. & Singleton, A. B. LRRK2: cause, risk, and mechanism. J. Parkinsons Dis. 3, 85–103 (2013).
pubmed: 23938341
pmcid: 3952583
doi: 10.3233/JPD-130192
Alessi, D. R. & Sammler, E. LRRK2 kinase in Parkinson’s disease. Science 360, 36–37 (2018).
pubmed: 29622645
doi: 10.1126/science.aar5683
Di Maio, R. et al. LRRK2 activation in idiopathic Parkinson’s disease. Sci. Transl Med. 10, eaar5429 (2018).
pubmed: 30045977
pmcid: 6344941
doi: 10.1126/scitranslmed.aar5429
Wong, M. M. K. et al. Neurodegeneration in SCA14 is associated with increased PKCγ kinase activity, mislocalization and aggregation. Acta Neuropathol. Commun. 6, 99 (2018).
pubmed: 30249303
pmcid: 6151931
doi: 10.1186/s40478-018-0600-7
Mabillard, H. & Sayer, J. A. The molecular genetics of Gordon syndrome. Genes 10, 986 (2019).
Di Maira, G. et al. The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. Oncogenesis 8, 61 (2019).
pubmed: 31641101
pmcid: 6805921
doi: 10.1038/s41389-019-0171-x
D’Amore, C., Borgo, C., Sarno, S. & Salvi, M. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance. Cell. Oncol. 43, 1003–1016 (2020).
doi: 10.1007/s13402-020-00566-w
Boumahdi, S. & de Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39–56 (2020). Interesting review of the emerging concept of drug-tolerant cells (also referred to as minimal residual disease) that can drive a drug-refractory phenotypic state that no longer depends on the drug-targeted pathway.
pubmed: 31601994
doi: 10.1038/s41573-019-0044-1
Oikkonen, J. et al. Prospective longitudinal ctDNA workflow reveals clinically actionable alterations in ovarian cancer. JCO Precis. Oncol. 3, 1–12 (2019).
Jiang, J. et al. Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer. BMC Cancer 20, 885 (2020).
pubmed: 32933495
pmcid: 7493404
doi: 10.1186/s12885-020-07340-z
Msaouel, P., Genovese, G., Gao, J., Sen, S. & Tannir, N. M. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment? Expert Opin. Ther. Targets 25, 141–151 (2021).
Xun, Q., Wang, Z., Hu, X., Ding, K. & Lu, X. Small-molecule CSF1R inhibitors as anticancer agents. Curr. Med. Chem. 27, 3944–3966 (2020).
pubmed: 31215373
doi: 10.2174/1573394715666190618121649
Moen, M. D., McKeage, K., Plosker, G. L. & Siddiqui, M. A. A. Imatinib. Drugs 67, 299–320 (2007).
pubmed: 17284091
doi: 10.2165/00003495-200767020-00010
Joensuu, H. et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J. Clin. Oncol. 34, 244–250 (2016).
pubmed: 26527782
doi: 10.1200/JCO.2015.62.9170
Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711–1723 (2020). First approval of a kinase inhibitor for reducing risk of recurrence in early-stage resectable NSCLC.
pubmed: 32955177
doi: 10.1056/NEJMoa2027071
Abbosh, C., Birkbak, N. J. & Swanton, C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat. Rev. Clin. Oncol. 15, 577–586 (2018). Overview of the technical challenges and feasibility of low-frequency mutation detection using NGS-based ctDNA profiling to deliver the potential paradigm shifting approach needed for early disease and minimal residual disease detection.
pubmed: 29968853
doi: 10.1038/s41571-018-0058-3
Whyte, J. L., Smith, A. A. & Helms, J. A. Wnt signaling and injury repair. Cold Spring Harb. Perspect. Biol. 4, a008078 (2012).
pubmed: 22723493
pmcid: 3405869
doi: 10.1101/cshperspect.a008078
Lu, X., Yang, J., Zhao, S. & Liu, S. Advances of Wnt signalling pathway in dental development and potential clinical application. Organogenesis 15, 101–110 (2019).
pubmed: 31482738
pmcid: 6804710
doi: 10.1080/15476278.2019.1656996
Neves, V. C., Babb, R., Chandrasekaran, D. & Sharpe, P. T. Promotion of natural tooth repair by small molecule GSK3 antagonists. Sci. Rep. 7, 39654 (2017). An interesting and unexpected example of the repurposing of a protein kinase inhibitor for a completely different clinical application.
pubmed: 28067250
pmcid: 5220443
doi: 10.1038/srep39654
Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785–789 (1995).
pubmed: 8524413
doi: 10.1038/378785a0
Hudis, C. A. Trastuzumab–mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 (2007).
pubmed: 17611206
doi: 10.1056/NEJMra043186
Garcia, J. et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 86, 102017 (2020).
pubmed: 32335505
doi: 10.1016/j.ctrv.2020.102017
Yun, J. et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR–MET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven NSCLC. Cancer Discov. 10, 1194–1209 (2020).
pubmed: 32414908
doi: 10.1158/2159-8290.CD-20-0116
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610–621 (2020).
pubmed: 31825192
doi: 10.1056/NEJMoa1914510
Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
pubmed: 23020162
pmcid: 5125250
doi: 10.1056/NEJMoa1209124
Hashimoto, Y. et al. A novel HER3-targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin. Cancer Res. 25, 7151–7161 (2019).
pubmed: 31471314
doi: 10.1158/1078-0432.CCR-19-1745
Zeng, S. et al. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges. Eur. J. Med. Chem. 210, 112981 (2020).
Henning, R. K. et al. Degradation of Akt using protein-catalyzed capture agents. J. Pept. Sci. 22, 196–200 (2016).
pubmed: 26880702
pmcid: 4883657
doi: 10.1002/psc.2858
Tovell, H. et al. Design and characterization of SGK3-PROTAC1, an isoform specific SGK3 kinase PROTAC degrader. ACS Chem. Biol. 14, 2024–2034 (2019).
pubmed: 31461270
pmcid: 6757289
doi: 10.1021/acschembio.9b00505
Burslem, G. M. et al. Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation. Cancer Res. 79, 4744–4753 (2019).
pubmed: 31311809
pmcid: 6893872
doi: 10.1158/0008-5472.CAN-19-1236
Lu, X., Smaill, J. B. & Ding, K. New promise and opportunities for allosteric kinase inhibitors. Angew. Chem. Int. Ed. 59, 13764–13776 (2020).
doi: 10.1002/anie.201914525
Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543, 733–737 (2017).
pubmed: 28329763
doi: 10.1038/nature21702
Hughes, T. P. et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N. Engl. J. Med. 381, 2315–2326 (2019). The first clinical data demonstrating efficacy of an allosteric ABL inhibitor in patients with CML who had failed prior ATP-competitive ABL inhibitors.
pubmed: 31826340
pmcid: 7724923
doi: 10.1056/NEJMoa1902328
To, C. et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov. 9, 926–943 (2019).
pubmed: 31092401
pmcid: 6664433
doi: 10.1158/2159-8290.CD-18-0903
Eide, C. A. et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36, 431–443.e435 (2019).